Articles tagged with Antidepressants
A recent review of opioid medicines for cancer pain found surprisingly large gaps in evidence regarding their true benefits. Non-steroidal anti-inflammatory drugs (NSAIDs) may be at least as effective as some opioids for background cancer pain, offering potential alternatives to reduce dependence and waning analgesia over time.
A small molecule called YM022 has been discovered to block aversive memory formation in mice, offering a new direction for developing anti-depressants. The study found that YM022 suppressed neuroplasticity-caused aversive memory formation and reduced depressive behaviors in mice.
A new study suggests that genetic testing for depression could lead to significant cost savings and improved patient outcomes. The test, known as pharmacogenomic testing, can help match patients with medications that are more likely to be effective and cause fewer side effects.
Researchers have identified a gene called LHPP that interacts with stress to mediate aspects of treatment-resistant MDD in an animal model. Increased expression of LHPP aggravated depression-like behaviors by dephosphorylating two protein kinases, CaMKIIα and ERK.
Acute sleep loss in mice increases dopamine release and enhances synaptic plasticity, leading to a rapid reversal of depression for several days. The prefrontal cortex plays a crucial role in this process, with neurons forming tiny protrusions that change in response to brain activity.
A study by Brigham and Women's Hospital researchers found no correlation between anxiety and depression in men on fertility treatment, nor was there a negative impact from antidepressant medication. Despite stress concerns, the study suggests men with anxiety should continue their treatment without fear of harming IVF outcomes.
Scientists identified two genes, ADRA2A and IRX1, that predispose individuals to Raynaud's phenomenon. The genes affect the body's ability to regulate blood vessel constriction, leading to white fingers and toes in response to cold or stress. The study provides new insights into the disease and potential treatment options, including th...
The ATLANTIS trial found that amitriptyline significantly improved IBS symptoms, with participants taking the medication reporting a bigger improvement in symptom scores after six months. The medication was well-tolerated and showed no significant impact on anxiety or depression scores.
A recent study published in Family Medicine and Community Health found that ChatGPT may be better than human doctors at following recognized treatment standards for clinical depression, without gender or social class biases. The AI technology provided fast, objective insights that supplemented traditional diagnostic methods and offered...
Researchers found that antidepressant escitalopram increases synaptic density in the brain over weeks, leading to greater brain plasticity. This explains why effects of antidepressants take time to kick-in, with significant differences in synapse density between treatment and placebo groups.
A study comparing exercise and antidepressants found that both treatments have similar benefits for mental health but exercise improved physical health markers. However, patients struggled to stick with the exercise routine due to higher drop-out rates.
A Phase IIIb study published in the New England Journal of Medicine found that esketamine nasal spray achieved higher remission rates (27.1%) compared to quetiapine extended-release (17.6%) in patients with treatment-resistant depression, indicating its potential as a targeted therapy for this population.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
The ESCAPE-TRD study found that esketamine nasal spray outperforms quetiapine in treating treatment-resistant major depression, with patients showing higher remission rates and reduced depressive symptoms. The results suggest esketamine as a safe and effective treatment option for those with treatment-resistant depression.
Researchers developed an electroencephalography-based model that accurately predicts response to specific antidepressant medications. The study suggests this method may help match patients with depression to optimized treatment, improving treatment outcomes.
A study by the University of Gothenburg reveals that obesity significantly worsens life expectancy and mortality risks in individuals with bipolar disorders. The findings show a rapid increase in BMI among those with bipolar disorders, leading to a higher risk of premature death and comorbidity.
A new study from Rice University found that antidepressants can reduce negative memories in depressed individuals while improving overall memory function. The study's lead author suggests that the medications shift memory dynamics toward healthy function and may help better select treatments depending on people's symptoms of depression.
A systematic review found that antidepressants are equally effective and safe for patients with both depression and physical health issues as those without. The study suggests that treating these patients with antidepressants can improve quality of life and reduce the course of physical disease.
Research based on the Trøndelag Health Study found that people in good physical shape fill fewer prescriptions for anxiety and depression medications. The study suggests that improving physical fitness can help prevent anxiety and depression, with men experiencing greater benefits from exercise than women.
Research found that selective serotonin reuptake inhibitor (SSRI) treatment for postnatal depression was associated with reduced child behavioral difficulties, ADHD symptoms, and maternal depression. The study also suggested long-term benefits of SSRI treatment on child outcomes up to five years after childbirth.
Researchers propose GABA-modulating treatments as potential therapeutic targets for depression's cognitive and affective symptoms. The study highlights the importance of GABA-A receptors in regulating balance and signals between neurons, and suggests compounds that promote or inhibit these receptors may alleviate depressive symptoms.
A clinical trial suggests that extending antidepressant treatment beyond eight weeks can help prevent depressive relapses in patients with bipolar disorder. The study found that continued treatment was associated with a 40% lower risk of relapse compared to tapering off and switching to a placebo.
Researchers from Boston University found that tianeptine provides rapid and lasting pain relief with a low risk of addiction, offering a safer alternative to current treatments. The study contributes to a larger set of data supporting the use of tianeptine for chronic pain conditions.
A Lehigh University professor has received $4 million in NIH grants to develop an AI-driven approach for precision mental health diagnosis and care. The project aims to identify biomarkers in the brain that can predict treatment response and personalize interventions for patients with depression and other mental disorders.
Research found that antidepressant prescriptions, particularly SSRIs, were associated with a 40% reduction in COVID-19 test positivity rates among mental health patients. The study suggests that antidepressants may have a preventative role against COVID-19 infection.
Researchers have deciphered the biosynthetic pathway of orcinol glucoside from Curculigo orchioides and successfully engineered its production in Yarrowia lipolytica. The resulting yields are significantly higher, exceeding 6,400-fold that of natural plant extraction.
A clinical trial of 403 patients found that ketamine treatment was non-inferior to ECT for treating non-psychotic treatment-resistant depression. Ketamine showed fewer side effects than ECT, with improved depressive symptoms and quality of life.
A Cochrane review found that most antidepressants used to manage chronic pain lack sufficient evidence of their effectiveness, with only duloxetine showing reliable pain relief. The review also revealed that harms from many commonly recommended drugs have not been well studied, posing a global public health concern.
KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.
A new study found that selective serotonin reuptake inhibitors (SSRIs) improved the quality of aging females' egg cells in roundworms by reducing embryonic death and chromosomal abnormalities. Replication in fruit flies confirmed the findings, suggesting a shared signaling system between species.
A study from Indiana University School of Medicine found that people with NAFLD have significantly decreased levels of the liver enzyme CYP2C19, which is important for medication processing. This decrease may lead to slower clearance of certain medications and reduced effectiveness of medicines like antidepressants and clopidogrel.
A recent study found that antidepressant fluoxetine facilitates the erasure of learned fear responses and enhances spatial learning in mice. The TrkB receptor in Parvalbumin interneurons is primarily responsible for this increased plasticity, suggesting a new target for treating psychiatric diseases.
A nationwide study in Denmark found that people living with HIV are at double the risk of depression and treatment with electroconvulsive therapy compared to controls. Siblings of PLWH also face an increased risk of depression, use of antidepressants, and suicide, but lower than for PLWH.
Overdose mortality among people aged 65 and older has quadrupled, driven by illicit drugs like fentanyl, heroin, and synthetic opioids. Researchers call for updated Medicare coverage and harm reduction supplies to curb the trend.
Researchers found that Matcha tea powder reduces depression in mice by activating dopaminergic neural circuits and improving mood. The study's results suggest that Matcha's antidepressant-like effects depend on the animal's prior mental state, with stress-susceptible mice showing a significant response.
A new article proposes a de novo billing code approach to address psychedelic therapy reimbursement concerns. Research using adult female rats suggests that psilocybin produces long-lasting normalization of pattern separation and forced swim test activities, indicating potential therapeutic benefits.
A team of Brown researchers has developed a new, highly accurate method for detecting antidepressants in patients using liquid chromatography tandem mass spectrometry. The technique requires minimal biological samples and can be fully automated using liquid-handling robots.
A comprehensive review of antidepressant use in chronic pain found that some classes were effective in treating certain conditions, while others showed unclear or unknown benefits. Serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine demonstrated efficacy for various pain conditions.
Researchers found that some antidepressant classes were effective in treating specific pain conditions, while others showed no benefits or unknown effects. The review of 26 systematic reviews involving over 25,000 participants suggests a more nuanced approach to prescribing antidepressants for chronic pain management is needed.
Researchers found that while some antidepressants are effective for certain pain conditions, most are either ineffective or the evidence is inconclusive. A more nuanced approach is needed when prescribing antidepressants for pain, say experts.
A new study found that sleep medications increase the risk of dementia in white adults. However, the relationship between sleep medications and dementia risk varies by medication type and socio-economic status. The study suggests that patients with poor sleep should consider alternative solutions before taking medications.
Researchers found that MAP4343 reversed excessive alcohol intake in mice modeling alcoholism and normalized blood levels of stress hormone corticosterone. The compound promotes assembly of tubulin proteins into microtubules, suggesting a possible effective treatment strategy for alcohol use disorder.
The American College of Physicians recommends using cognitive behavioral therapy (CBT) or second-generation antidepressants as initial treatment for adults with moderate to severe major depressive disorder. The guideline also suggests considering combination therapy and discussing patient preferences when selecting a treatment.
Researchers found that selective serotonin reuptake inhibitors (SSRIs) affect reinforcement learning, leading to reduced sensitivity to rewards and emotional dullness. The study provides new insights into the mechanisms behind this common side effect.
Researchers found that clonidine, a common blood pressure medication, can reduce the consolidation of traumatic memories in PTSD patients. By interacting with the adrenergic receptor axis, clonidine interferes with cofilin's ability to form mushroom-shaped dendritic spines, which are essential for memory formation. This suggests that c...
Research from University of Virginia Health System suggests antidepressants can heighten lifelong brain changes in babies, such as autism, when combined with infection or inflammation during pregnancy. SSRIs interact powerfully with the mother's body, causing harmful changes in the placenta and developing brain.
Researchers found reduced serotonin release capacity in individuals with depression, suggesting a blunted serotonin system. The study used novel imaging techniques to measure serotonin levels in the brain, providing crucial insights into the pathology of depression.
A new study published in JAMA Psychiatry finds that patients with treatment-resistant depression have a 23% higher risk of death, as well as significantly more outpatient care and hospitalization days. The researchers emphasize the importance of identifying patients at risk of developing treatment-resistant depression to improve their ...
A review of over 100 scientific articles suggests that the safety of antidepressants during pregnancy is endorsed by science, but their effects on fetal neurodevelopment are poorly understood. Brazilian researchers propose using lab-grown mini-brains to investigate this impact and identify potential alterations.
A new study reveals ketamine dramatically changes neuronal activity patterns in the cerebral cortex, turning off active neurons and turning on silent ones. This switch in brain activity may impact our understanding of ketamine's antidepressant effects and future research in neuropsychiatry.
Researchers have identified potential new lead compounds for treating depression and anxiety disorders, which display reduced risk of drug abuse and adverse effects. These substances, derived from synthetic cathinone compounds, are known to release serotonin without significantly increasing dopamine levels in the brain.
Researchers developed a novel intranasal delivery system that utilizes the trigeminal nerve to deliver antidepressant drugs to the brain. The system showed efficacy at delivering the same dose as intracerebroventricular administration, highlighting a potential new approach for treating depression and other neurological disorders.
Researchers are investigating the antidepressant and anxiolytic properties of psilocybin and cannabis to improve treatment options for mental illnesses. The findings suggest that these compounds may offer new avenues for symptom relief in a range of mental health conditions.
New research reveals profound effects of pregnancy on maternal brain physiology, mood, and behavior. Maternal mental health conditions like depression and anxiety affect 20% of new mothers in the US, with untreated cases having long-term negative impacts.
Researchers conducted the largest clinical trial to date of psilocybin, finding a statistically significant rapid reduction in symptoms of depression. The study suggests that COMP360 psilocybin with psychological support could be an effective treatment strategy for people with treatment-resistant depression.
Researchers at Intermountain Healthcare found that taking selective serotonin reuptake inhibitors (SSRIs) does not reduce the severity of COVID-19 illness or death. Not being on an SSRI was associated with a lower risk of hospitalization and death from COVID.
A multicentre clinical trial found that a single dose of COMP360 psilocybin significantly reduced depression symptoms in participants with treatment-resistant depression. The study, involving 233 participants, showed improved outcomes for those receiving the 25mg dose compared to the control group.
A Cornell University researcher is using optical microscopy and other tools to map the brain's neural response to psychedelics. The study aims to develop fast-acting antidepressants and treatments for substance-use disorders and cluster headaches.
A meta-analysis of six studies concludes that electroconvulsive therapy (ECT) is more effective than ketamine in quickly relieving major depression symptoms. The analysis, published in JAMA Psychiatry, found no significant differences in ECT's success rate across various age groups and geographic locations.
A recent study identifies a specific gene, GNL3, that regulates neural proliferation in response to lithium, which is used to treat bipolar disorder. This gene plays an important role in brain function and has been implicated in risk for bipolar disorder, schizophrenia, and inter-individual variations in intelligence.